We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

56 hedge funds and large institutions have $12.1M invested in Oramed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more call options, than puts

Call options by funds: $136K | Put options by funds: $52K

101% more capital invested

Capital invested by funds: $5.99M → $12.1M (+$6.07M)

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

7.25% more ownership

Funds ownership: 5.7% → 12.95% (+7.2%)

0% more funds holding

Funds holding: 56 → 56 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

Holders
56
Holders Change
–
Holders Change %
0%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
17
Reduced
11
Closed
9
Calls
$136K
Puts
$52K
Net Calls
+$84K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
+$2.24M
2
BFM
Boothbay Fund Management
New York
+$1.12M
3
BCM
BML Capital Management
Indiana
+$1.03M
4
Renaissance Technologies
Renaissance Technologies
New York
+$634K
5
Bank of America
Bank of America
North Carolina
+$536K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$401K
2
GCP
GSA Capital Partners
United Kingdom
-$232K
3
Citigroup
Citigroup
New York
-$108K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$71.2K
5
VF
Virtu Financial
New York
-$45K
Name Holding Trade Value Shares
Change 		Change in
Stake
NEWAS
26
N.E.W. Advisory Services
Wisconsin
$29.9K – – –
AS
27
Altshuler Shaham
Israel
$29.6K – – –
Wealth Enhancement Advisory Services
28
Wealth Enhancement Advisory Services
Minnesota
$27.5K – – –
CAM
29
Close Asset Management
United Kingdom
$26K – – –
HF
30
HRT Financial
New York
$25K +$23.8K +11,165 New
GJIA
31
Glass Jacobson Investment Advisors
Maryland
$24.3K -$3.66K -1,715 -14%
Group One Trading
32
Group One Trading
Illinois
$24K -$214 -100 -1%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$21K +$8.48K +3,971 +75%
A
34
AJOVista
Massachusetts
$19.4K +$17.9K +8,390 New
Osaic Holdings
35
Osaic Holdings
Arizona
$19.4K -$24.1K -11,300 -57%
BCM
36
Bourgeon Capital Management
Connecticut
$13K – – –
UBS Group
37
UBS Group
Switzerland
$11.7K -$2.44K -1,140 -18%
HNB
38
Huntington National Bank
Ohio
$11.6K – – –
Wells Fargo
39
Wells Fargo
California
$10.4K – – –
LA
40
LM Advisors
California
$5.78K +$5.34K +2,500 New
QT
41
Quantbot Technologies
New York
$5.31K +$2.92K +1,369 +147%
ME
42
McIlrath & Eck
Washington
$4.62K – – –
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$4.23K – – –
Northwestern Mutual Wealth Management
44
Northwestern Mutual Wealth Management
Wisconsin
$3.64K – – –
IA
45
IFP Advisors
Florida
$3.46K -$502 -235 -14%
CHC
46
City Holding Co
West Virginia
$2.46K – – –
CFGS
47
Concourse Financial Group Securities
Alabama
$2.31K – – –
Fidelity Investments
48
Fidelity Investments
Massachusetts
$2.08K – – –
NFSG
49
Newbridge Financial Services Group
Florida
$1.52K – – –
TRCT
50
Tower Research Capital (TRC)
New York
$1.35K -$3.54K -1,656 -74%
1
2
3

ORMP Hedge Fund Activity: Q4 2023 in Review

56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2023, worth a combined $12.1M — up 101% from $5.99M a quarter earlier.

Fund positioning in ORMP was balanced in Q4 2023: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 11 trimmed.

The largest buyer was Murchinson, opening a new position worth an estimated $2.24M. The largest seller was Goldman Sachs, exiting entirely with an estimated $401K sold.

  • 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $12.1M of Oramed Pharmaceuticals stock for Q4 2023, up 101% quarter-over-quarter.
  • 9 funds opened new Oramed Pharmaceuticals positions in Q4 2023 and 9 closed out, a net change of 0 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2023 was Murchinson, an estimated $2.24M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2023 was Goldman Sachs, an estimated $401K sold.

Based on aggregated 13F filings for Q4 2023.